Clinical Trials
2 trialsNCT06266091 2025-07-20
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
Wuhan YZY Biopharma Co., Ltd.
Phase 2 Completed
NCT06433869 2024-05-30
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
Sun Yat-sen University
Phase 2 Recruiting